TOKYO, July 6, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's Biologics…Original Article
Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application
